MX2020008323A - Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino. - Google Patents
Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino.Info
- Publication number
- MX2020008323A MX2020008323A MX2020008323A MX2020008323A MX2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A MX 2020008323 A MX2020008323 A MX 2020008323A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- agent
- chemioprotective
- antiplatinum
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628824P | 2018-02-09 | 2018-02-09 | |
| PCT/US2019/017334 WO2019157370A1 (en) | 2018-02-09 | 2019-02-08 | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008323A true MX2020008323A (es) | 2020-10-14 |
Family
ID=67549759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008323A MX2020008323A (es) | 2018-02-09 | 2019-02-08 | Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino. |
| MX2023001963A MX2023001963A (es) | 2018-02-09 | 2020-08-07 | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001963A MX2023001963A (es) | 2018-02-09 | 2020-08-07 | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10709732B2 (enExample) |
| EP (1) | EP3749309A4 (enExample) |
| JP (3) | JP7492917B2 (enExample) |
| KR (1) | KR102860981B1 (enExample) |
| CN (1) | CN112020359A (enExample) |
| AU (1) | AU2019218232B2 (enExample) |
| BR (1) | BR112020016059A2 (enExample) |
| CA (1) | CA3090783A1 (enExample) |
| IL (1) | IL276569B2 (enExample) |
| MX (2) | MX2020008323A (enExample) |
| SG (1) | SG11202007595WA (enExample) |
| WO (1) | WO2019157370A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018039375A1 (en) | 2016-08-23 | 2018-03-01 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| BR112020016059A2 (pt) | 2018-02-09 | 2020-12-08 | Decibel Therapeutics, Inc. | Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina |
| IL325122A (en) | 2018-02-22 | 2026-02-01 | Akouos Inc | Compositions and methods for treating non-age-related hearing impairment in humans |
| BR112021000021A2 (pt) * | 2018-07-03 | 2021-03-30 | Fennec Pharmaceuticals, Inc. | Tiossulfato de sódio anidro e formulações do mesmo |
| US20220054640A1 (en) * | 2018-12-11 | 2022-02-24 | Decibel Therapeutics, Inc. | Compositions and methods for the delivery of therapeutic agents across the round window membrane |
| US10813947B1 (en) | 2019-05-31 | 2020-10-27 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
| WO2020256548A1 (en) * | 2019-06-19 | 2020-12-24 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Sodium thiosulfate gel for preventing or reducing hearing loss |
| CN114845721A (zh) * | 2019-10-30 | 2022-08-02 | 奥德纳米有限公司 | 用于药物诱导的耳毒性的耳用制剂 |
| CA3168055A1 (en) | 2020-02-21 | 2021-08-26 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| US20260027327A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Otic drug delivery system and methods |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6649621B2 (en) | 1997-12-16 | 2003-11-18 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
| US6497902B1 (en) | 1999-12-01 | 2002-12-24 | The Regents Of The University Of Michigan | Ionically crosslinked hydrogels with adjustable gelation time |
| KR20030014208A (ko) | 2000-04-26 | 2003-02-15 | 오레곤 헬스 사이언시즈 유니버시티 | 티올계 화학보호제 화합물의 투여 |
| EP1404689A1 (en) * | 2001-07-02 | 2004-04-07 | Debiopharm S.A. | Oxaliplatin active substance with a very low content of oxalic acid |
| US7790699B2 (en) | 2004-10-12 | 2010-09-07 | Fmc Biopolymer As | Self-gelling alginate systems and uses thereof |
| CA2620374C (en) | 2005-09-28 | 2012-12-11 | Thomas Meyer | Pharmaceutical compositions for the treatment of inner ear disorders |
| WO2008056822A1 (en) | 2006-11-09 | 2008-05-15 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component |
| WO2009132050A2 (en) * | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| US20100016450A1 (en) | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
| US8784870B2 (en) * | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| JP5905387B2 (ja) * | 2009-07-08 | 2016-04-20 | ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズＨｏｐｅ Ｍｅｄｉｃａｌ Ｅｎｔｅｒｐｒｉｓｅｓ，Ｉｎｃ．Ｄｂａ Ｈｏｐｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ | チオ硫酸ナトリウムを含有する薬学的組成物 |
| EP3501521A1 (en) | 2011-02-18 | 2019-06-26 | Otonomy, Inc. | Prevention of and recovery from drug-induced ototoxicity |
| US10130514B2 (en) | 2011-09-26 | 2018-11-20 | Incube Labs, Llc | System and method for delivery of a therapeutic agent to the inner ear |
| FR2992861B1 (fr) * | 2012-07-09 | 2014-10-17 | Probionov | Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles |
| JP7074663B6 (ja) * | 2015-05-28 | 2022-08-01 | ベイラー カレッジ オブ メディスン | グルタチオンレベルを改善するためのｎ－アセチルシステイン及びグリシンの補給の効果 |
| AU2016304585B2 (en) | 2015-08-05 | 2023-04-06 | Children's Medical Center Corporation | Compositions with permeation enhancers for drug delivery |
| US20190038756A1 (en) | 2016-02-10 | 2019-02-07 | Cocoon Biotech Inc. | Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs, silk fibroin, and a gelling agent and uses thereof |
| EP3478269A4 (en) | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
| EP3570826A4 (en) | 2017-01-19 | 2020-09-23 | Otologic Pharmaceutics, Inc. | N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES |
| US10596190B2 (en) | 2017-11-29 | 2020-03-24 | Oregon Health & Science University | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
| WO2019118330A1 (en) | 2017-12-12 | 2019-06-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear |
| US11918653B2 (en) | 2017-12-22 | 2024-03-05 | Dompé Farmaceutici S.P.A. | Triglyceride otic formulations and uses thereof |
| US10946443B2 (en) | 2018-01-08 | 2021-03-16 | Hamilton Sundstrand Corporation | Removal of unfused powder from an additive-manufactured part using piezoelectric transducers |
| WO2019140012A1 (en) | 2018-01-09 | 2019-07-18 | Otonomy, Inc. | Growth factor otic formulations |
| WO2019154895A1 (en) | 2018-02-08 | 2019-08-15 | Strekin Ag | Gel formulation for preventing or treating hearing loss |
| BR112020016059A2 (pt) | 2018-02-09 | 2020-12-08 | Decibel Therapeutics, Inc. | Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina |
| US20210186943A1 (en) | 2018-04-25 | 2021-06-24 | Otonomy, Inc. | Otic formulations for drug-induced ototoxicity |
| IT201800006566A1 (it) | 2018-06-21 | 2019-12-21 | Composizione per prevenire e trattare disordini uditivi e vestibolari | |
| BR112021000021A2 (pt) | 2018-07-03 | 2021-03-30 | Fennec Pharmaceuticals, Inc. | Tiossulfato de sódio anidro e formulações do mesmo |
| US10813947B1 (en) | 2019-05-31 | 2020-10-27 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
| WO2020256548A1 (en) | 2019-06-19 | 2020-12-24 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Sodium thiosulfate gel for preventing or reducing hearing loss |
-
2019
- 2019-02-08 BR BR112020016059-8A patent/BR112020016059A2/pt unknown
- 2019-02-08 JP JP2020564795A patent/JP7492917B2/ja active Active
- 2019-02-08 CA CA3090783A patent/CA3090783A1/en active Pending
- 2019-02-08 WO PCT/US2019/017334 patent/WO2019157370A1/en not_active Ceased
- 2019-02-08 AU AU2019218232A patent/AU2019218232B2/en active Active
- 2019-02-08 EP EP19751242.9A patent/EP3749309A4/en active Pending
- 2019-02-08 CN CN201980023532.8A patent/CN112020359A/zh active Pending
- 2019-02-08 KR KR1020207026015A patent/KR102860981B1/ko active Active
- 2019-02-08 SG SG11202007595WA patent/SG11202007595WA/en unknown
- 2019-02-08 MX MX2020008323A patent/MX2020008323A/es unknown
- 2019-07-19 US US16/517,284 patent/US10709732B2/en active Active
-
2020
- 2020-07-13 US US16/927,777 patent/US11071751B2/en active Active
- 2020-08-06 IL IL276569A patent/IL276569B2/en unknown
- 2020-08-07 MX MX2023001963A patent/MX2023001963A/es unknown
-
2021
- 2021-06-21 US US17/352,712 patent/US11857567B2/en active Active
-
2023
- 2023-11-30 US US18/524,148 patent/US20240350533A1/en not_active Abandoned
-
2024
- 2024-05-20 JP JP2024081711A patent/JP2024098070A/ja active Pending
-
2025
- 2025-03-31 US US19/096,329 patent/US20250381219A1/en active Pending
-
2026
- 2026-05-01 JP JP2026077143A patent/JP2026119177A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020016059A2 (pt) | 2020-12-08 |
| SG11202007595WA (en) | 2020-09-29 |
| JP2026119177A (ja) | 2026-07-16 |
| EP3749309A1 (en) | 2020-12-16 |
| US20210308176A1 (en) | 2021-10-07 |
| CA3090783A1 (en) | 2019-08-15 |
| US20200338119A1 (en) | 2020-10-29 |
| US11857567B2 (en) | 2024-01-02 |
| MX2023001963A (es) | 2023-02-23 |
| WO2019157370A1 (en) | 2019-08-15 |
| US20240350533A1 (en) | 2024-10-24 |
| JP7492917B2 (ja) | 2024-05-30 |
| US11071751B2 (en) | 2021-07-27 |
| KR102860981B1 (ko) | 2025-09-18 |
| CN112020359A (zh) | 2020-12-01 |
| AU2019218232A1 (en) | 2020-09-24 |
| IL276569B2 (en) | 2023-06-01 |
| AU2019218232B2 (en) | 2024-12-19 |
| JP2024098070A (ja) | 2024-07-19 |
| IL276569A (en) | 2020-09-30 |
| US20250381219A1 (en) | 2025-12-18 |
| JP2021513558A (ja) | 2021-05-27 |
| US20190336524A1 (en) | 2019-11-07 |
| EP3749309A4 (en) | 2021-12-08 |
| US10709732B2 (en) | 2020-07-14 |
| KR20200129107A (ko) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
| CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| CL2020001312A1 (es) | Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425). | |
| MX390014B (es) | Compuestos de dinucleótidos cíclicos y métodos de uso. | |
| CL2017000240A1 (es) | Compuestos activos hacia bromodominios | |
| MX2016015636A (es) | Formulaciones cannabinoides estables. | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| CY1122829T1 (el) | Φαρμακευτικη συνθεση για νευροπαθητικο πονο | |
| CL2020002624A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| MX2019014772A (es) | Formulaciones en gel de bisfosfocinas y usos de estas. | |
| UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
| CO2019013013A2 (es) | Inhibidores pirazólicos de magl | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| DOP2021000170A (es) | Formulacion de anticuerpos terapeuticos | |
| CO2017003290A2 (es) | Composiciones y kits para desbridación enzimática y metodos de uso de los mismos | |
| MX386732B (es) | Composición farmacéutica de corticosteroide soluble. | |
| CL2020002519A1 (es) | Composiciones de erenumab y usos de las mismas | |
| EP4028059C0 (en) | STABLE MEDICINAL COMPOSITIONS OF CANNABidiol | |
| EP3897593A4 (en) | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | |
| AR112448A1 (es) | Derivados de xantina sustituidos | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. |